Precision AQ

Precision AQ is a commercialization partner to the pharmaceutical and biotechnology industry, working with clients across a product's entire lifecycle, from early pipeline through to post-launch optimization. The firm operates globally and employs more than 1,200 people. It works with companies in the pharmaceuticals, biotechnology, biopharma, healthcare and life sciences sectors, and has supported a significant portion of FDA-approved drug launches and label expansions.

Its service lines span commercialization strategy, value and access, medical communications, investor relations, brand strategy and marketing, and data solutions. The value and access practice supports market access and value demonstration for pharmaceutical products; medical communications serves medical and scientific audiences; investor relations serves biopharma clients; brand strategy and marketing operates across the product lifecycle; and data solutions integrates technology, expertise and strategic guidance to organize complex data.

The team includes former access decision-makers, clinicians, scientists, strategists and communications professionals. The company describes its approach as combining data with human insight - "where IQ meets EQ" - with a focus on making access to life-changing medicines actionable and precise.

Precision AQ was formerly known as Precision Value & Health and was formally reintroduced under its current name in May 2024; the initials AQ stand for "Access Quotient". The firm operates under the Precision Medicine Group umbrella. Further information is available at https://precisionaq.com/.